cas 31181-90-5|| where to buy 5-bromopyridine-2-carbaldehyde

Nombre del producto:5-bromopyridine-2-carbaldehyde

IUPAC Name:5-bromopyridine-2-carbaldehyde

Unidad de embalaje	Stock disponible	Precio($)
CM104127-25g	in stock	ǲƤ
CM104127-100g	in stock	ȷǲǕ
CM104127-500g	1-2 Weeks	ȦȦƋȦ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 31181-90-5 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :31181-90-5; Fórmula molecular:C6H4BrNO; Punto de fusión:-; Código de sonrisas:[H]C(=O)C1=NC=C(Br)C=C1; Densidad:

: Número de catálogo:CM104127; Peso molecular:186.01; Punto de ebullición:237.7°C at 760 mmHg; Nº Mdl:MFCD04112535; Almacenamiento:Keep in Inert atmosphere, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Camizestrant; Recently, Evaluate Pharma released an analysis report on the trends in the biopharmaceutical industry in 2024. The report mentioned 10 potential key R&D pipelines, including the small molecule drug camizestrant. Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.